stockportfolio.pro
Stocks / AVR vs PCRX
AVR vs PCRX
Anteris Technologies Global Corp. and Pacira BioSciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Anteris Technologies Global Corp. (AVR) | Pacira BioSciences, Inc. (PCRX) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $1.91M | $726.41M |
| Net income (latest FY) | $-94.14M | $7.03M |
| Revenue growth (5y CAGR) | -24.3% | 11.1% |
| Net margin | -4921.3% | 1.0% |
| Return on equity | 101230.1% | 1.0% |
| P/E ratio | — | 180.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 5 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AVR — free Open PCRX — freeFrequently asked questions
Which is bigger, AVR or PCRX?
Pacira BioSciences, Inc. is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, AVR or PCRX?
Over the last five fiscal years, Pacira BioSciences, Inc. grew revenue faster — 11.1%/yr versus -24.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.